Sexual-biased necroinflammation is revealed as a predictor of bevacizumab benefit in Glioblastoma. Hiller-Vallina S, Mondejar-Ruescas L, Caamano-Moreno M, Comitre-Mariano B, et al. Neuro Oncol 2024 Feb 27:noae033. doi: 10.1093.

Read + Share

Amedeo Smart

Independent Medical Education

Hiller-Vallina S, Mondejar-Ruescas L, Caamano-Moreno M, Comitre-Mariano B, et al. Sexual-biased necroinflammation is revealed as a predictor of bevacizumab benefit in Glioblastoma. Neuro Oncol 2024 Feb 27:noae033. doi: 10.1093.
PMID: 38411438